Latest news
Targeting Autophagy May Overcome Cisplatin Resistance in Gastric Cancer - Bioengineer.orgBioengineer.org · Fri, 07 Aug 2026 03:53:49 GMTTargeting the roots of head and neck cancer: Why MDA-9 matters - Drug Target ReviewDrug Target Review · Thu, 06 Aug 2026 11:36:51 GMTNeoadjuvant Sacituzumab Govitecan in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Brigida Maiorano - UroTodayUroToday · Thu, 06 Aug 2026 00:32:57 GMTHealth Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after - PR Newswire CanadaPR Newswire Canada · Wed, 05 Aug 2026 15:00:00 GMTEnfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer - The ASCO PostThe ASCO Post · Mon, 03 Aug 2026 15:31:59 GMTEnfortumab Vedotin–Pembrolizumab Improves Survival in Cisplatin-Eligible Bladder Cancer - OncodailyOncodaily · Fri, 31 Jul 2026 07:00:00 GMTMatthew Galsky, MD, on the changing role of cisplatin eligibility in MIBC - Urology TimesUrology Times · Thu, 30 Jul 2026 18:35:48 GMT